Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Parallel Controlled, Non-inferiority Design Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) Administered to Participants Aged 10 to 60 Years With Different Immunization Schedules

NCT07028801 is registered in ClinicalTrials.gov with Ningbo Rongan Biological Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07028801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Parallel Controlled, Non-inferiority Design Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) Administered to Participants Aged 10 to 60 Years With Different Immunization Schedules
Lead sponsor
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
March 31, 2026
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rabies